Structural basis for potent neutralization of human respirovirus type 3 by protective single-domain camelid antibodies

被引:1
|
作者
Johnson, Nicole V. [1 ]
van Scherpenzeel, Revina C. [2 ]
Bakkers, Mark J. G. [3 ,4 ]
Ramamohan, Ajit R. [1 ]
van Overveld, Daan [3 ]
Le, Lam [3 ]
Langedijk, Johannes P. M. [3 ,4 ]
Kolkman, Joost A. [2 ]
McLellan, Jason S. [1 ]
机构
[1] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA
[2] Janssen Infect Dis & Vaccines, B-2340 Beerse, Belgium
[3] Janssen Vaccines & Prevent BV, Leiden, Netherlands
[4] ForgeBo BV, Amsterdam, Netherlands
关键词
PARAINFLUENZA VIRUS TYPE-3; RESPIRATORY SYNCYTIAL VIRUS; 5 FUSION PROTEIN; HEMAGGLUTININ-NEURAMINIDASE; F-PROTEIN; IN-VITRO; INFECTION; TRIMER; MODEL; SITE;
D O I
10.1038/s41467-024-49757-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Respirovirus 3 is a leading cause of severe acute respiratory infections in vulnerable human populations. Entry into host cells is facilitated by the attachment glycoprotein and the fusion glycoprotein (F). Because of its crucial role, F represents an attractive therapeutic target. Here, we identify 13 F-directed heavy-chain-only antibody fragments that neutralize recombinant respirovirus 3. High-resolution cryo-EM structures of antibody fragments bound to the prefusion conformation of F reveal three distinct, previously uncharacterized epitopes. All three antibody fragments bind quaternary epitopes on F, suggesting mechanisms for neutralization that may include stabilization of the prefusion conformation. Studies in cotton rats demonstrate the prophylactic efficacy of these antibody fragments in reducing viral load in the lungs and nasal passages. These data highlight the potential of heavy-chain-only antibody fragments as effective interventions against respirovirus 3 infection and identify neutralizing epitopes that can be targeted for therapeutic development. Respirovirus 3 is a major cause of respiratory infection. Here authors generate and explore heavy-chain antibody fragments that target the fusion protein and test these in vitro and in an animal model.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
    Wrapp, Daniel
    De Vlieger, Dorien
    Corbett, Kizzmekia S.
    Torres, Gretel M.
    Wang, Nianshuang
    Van Breedam, Wander
    Roose, Kenny
    van Schie, Loes
    Hoffmann, Markus
    Poehlmann, Stefan
    Graham, Barney S.
    Callewaert, Nico
    Schepens, Bert
    Saelens, Xavier
    McLellan, Jason S.
    [J]. CELL, 2020, 181 (05) : 1004 - +
  • [2] Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies (vol 181, pg 1004, 2020)
    Wrapp, Daniel
    De Vlieger, Dorien
    Corbett, Kizzmekia S.
    Torres, Gretel M.
    Wang, Nianshuang
    Van Breedam, Wander
    Roose, Kenny
    van Schie, Loes
    Hoffmann, Markus
    Pohlmann, Stefan
    Graham, Barney S.
    Callewaert, Nico
    Schepens, Bert
    Saelens, Xavier
    McLellan, Jason S.
    [J]. CELL, 2020, 181 (06) : 1436 - 1441
  • [3] Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms
    Brilhante-da-Silva, Nairo
    de Oliveira Sousa, Rosa Maria
    Arruda, Andrelisse
    dos Santos, Eliza Lima
    Marinho, Anna Carolina Machado
    Stabeli, Rodrigo Guerino
    Fernandes, Carla Freire Celedonio
    Pereira, Soraya dos Santos
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2021, 25 (04) : 439 - 456
  • [4] Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms
    Nairo Brilhante-da-Silva
    Rosa Maria de Oliveira Sousa
    Andrelisse Arruda
    Eliza Lima dos Santos
    Anna Carolina Machado Marinho
    Rodrigo Guerino Stabeli
    Carla Freire Celedonio Fernandes
    Soraya dos Santos Pereira
    [J]. Molecular Diagnosis & Therapy, 2021, 25 : 439 - 456
  • [5] Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling
    Rossotti, Martin A.
    Henry, Kevin A.
    van Faassen, Henk
    Tanha, Jamshid
    Callaghan, Deborah
    Hussack, Greg
    Arbabi-Ghahroudi, Mehdi
    MacKenzie, C. Roger
    [J]. BIOCHEMICAL JOURNAL, 2019, 476 : 39 - 50
  • [6] Physicochemical differences between camelid single-domain antibodies and mammalian antibodies
    Eskier, Nazli Eda
    Eskier, Doga
    Firuzan, Esin
    Uzunlar, Sibel Kalyoncu
    [J]. TURKISH JOURNAL OF BIOLOGY, 2023, 47 (06)
  • [7] CAMELID SINGLE-DOMAIN ANTIBODIES: MORE NEW FEATURES.
    Decanniere, K.
    Desmyter, A.
    Lauwereys, M.
    Muyldermans, S.
    Wyns, L.
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 1999, 55 : 349 - 350
  • [8] Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook
    Arbabi-Ghahroudi, Mehdi
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [9] Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments
    Arbabi-Ghahroudi, Mehdi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (09)
  • [10] Camelid single-domain antibodies as a therapeutic approach for familial amyloidosis of the Finnish type (FAF)
    Van Overbeke, W.
    Guaraldo, M.
    Vandekerckhove, J.
    De Ganck, A.
    Gettemans, J.
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2010, 17 : 97 - 97